HMG-CoA Cancer Research Results

HMG-CoA, Mevalonate pathway: Click to Expand ⟱
Source:
Type:
HMG‐CoA (3‐hydroxy-3‐methylglutaryl‐coenzyme A) 
Mevalonate pathway → Primary pathway entry
-HMG-CoA reductase (HMGCR) → rate-limiting node / druggable target
-Downstream nodes: prenylation, cholesterol synthesis, CoQ
HMG‐CoA is not a single enzyme but rather a key metabolic intermediate in the mevalonate pathway that underlies cholesterol and isoprenoid biosynthesis.
– HMG‐CoA is a pivotal intermediate formed from acetyl‐CoA (via the enzyme HMG‐CoA synthase) that subsequently undergoes reduction (via HMG‐CoA reductase) to produce mevalonate.
– The mevalonate pathway supplies cholesterol and other isoprenoids, which are essential for membrane biogenesis, protein prenylation, and other cellular functions that support cell proliferation and survival.
– The availability of HMG‐CoA and subsequent metabolites has implications for modifying cell signaling pathways, including those involved in the regulation of cell growth, differentiation, and apoptosis.
– Markers of an activated mevalonate pathway (such as increased expression of HMG‐CoA synthase or HMG‐CoA reductase) have been associated with aggressive tumor phenotypes in several cancer types, including breast, prostate, and liver cancers.
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACLY↓, 1,   HMG-CoA↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   MUC1↑, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 4,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 11

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: HMG-CoA, Mevalonate pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:1143  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page